Secobarbital

Barbiturates are a class of around 12 compounds derivatised from barbituric acid. They are central nervous system (CNS) depressants and can be used as sedatives, hypnotics, anaesthetics and anti-epileptic drugs. Barbiturates can be divided into three main groups according to their duration of action. The ultra-short-acting barbiturates are used clinically as anaesthetics whilst the long-acting barbiturates have anti-convulsant properties. The short-acting compounds are typically used as hypnotics (1, 2). The short-acting barbiturates are extensively metabolised by the liver to more pharmacologically inactive hydroxylated compounds. Only a small proportion of parent compound (<0.2%) appears in the urine collected after 24 hours. However, with large doses, there is usually sufficient of the parent compound present to give an adequate response and some of the hydroxylated metabolites will also cross-react in immunoassays (1).\n\nApplications: \nSuitable for use in ELISA. Other applications not tested.\n \nRecommended Dilution:\nELISA: 5ug/ml\nOptimal dilutions to be determined by the researcher.\n\nMatch To; HRP9293\n\nStorage and Stability:\nMay be stored at 4 degrees C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

S0600-02A

Size

100ul

Applications

ELISA

Hosts

Sheep

Form

Supplied as a liquid in 20mM phosphate, 150mM sodium chloride, pH 7.2, 0.09% sodium azide.

P Type

Pab

Purity

Purified

References

1. Galloway J.H. and Marsh I.D. Detection of drug misuse and addictive challenge. J. Clin. Pathol.1999. 52 (10): 713-718. 2. Manchikanti, L. Prescription drug abuse: what is being done to address this new drug epidemic? Testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources. Pain Physician. 2006. 9(4): 287-321.

Additional Info

Recognizes Secobarbital.